VISUALIZE
BRIGHTER FUTURES

ASCEND

ASCEND is a clinical trial for adults with advanced cancer, including cancer that has spread to other parts of the body (metastatic). It is assessing the safety, tolerability, and preliminary effectiveness of an investigational therapy called CR-001.

CR-001 is an investigational immunotherapy targeting PD-1 and VEGF in a “bispecific antibody” design developed to fight cancer in multiple ways. It works by:

Helping the body’s immune system find and attack cancer cells by blocking PD-1, a protein tumors use to hide from immune defenses.
Changing the tumor environment and slowing tumor growth by blocking VEGF, which not only reduces blood vessel formation but may also help activate additional immune defenses against the cancer.

By targeting these pathways at the same time, CR-001 may help the immune system recognize and attack tumor cells, while also cutting off the tumor’s blood supply. CR-001 may also be able to concentrate in the tumor area, potentially reducing side effects in healthy tissue. In preclinical studies, CR-001 demonstrated robust antitumor effects.  

You may be able to join ASCEND if you:

  • Are 18 years or older
  • Have one of the types of cancer being studied (liver, bile duct, uterine, cervical, ovarian, stomach, colorectal, or lung) and it has progressed or spread
  • Meet additional criteria for the study. The study staff will help you determine if you are eligible to participate
For more information about the ASCEND clinical trial, including trial sites, visit clinicaltrials.gov (NCT07335497) or email clinicaltrials@crescentbiopharma.com.